262 related articles for article (PubMed ID: 26071277)
1. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
Simon N; Finzi J; Cayla G; Montalescot G; Collet JP; Hulot JS
Eur J Clin Pharmacol; 2015 Sep; 71(9):1059-66. PubMed ID: 26071277
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
Angiolillo DJ; Gibson CM; Cheng S; Ollier C; Nicolas O; Bergougnan L; Perrin L; LaCreta FP; Hurbin F; Dubar M
Clin Pharmacol Ther; 2011 Jan; 89(1):65-74. PubMed ID: 20844485
[TBL] [Abstract][Full Text] [Related]
3. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
[TBL] [Abstract][Full Text] [Related]
4. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
Collet JP; Hulot JS; Anzaha G; Pena A; Chastre T; Caron C; Silvain J; Cayla G; Bellemain-Appaix A; Vignalou JB; Galier S; Barthélémy O; Beygui F; Gallois V; Montalescot G;
JACC Cardiovasc Interv; 2011 Apr; 4(4):392-402. PubMed ID: 21511218
[TBL] [Abstract][Full Text] [Related]
5. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Sibbing D; Morath T; Stegherr J; Braun S; Vogt W; Hadamitzky M; Schömig A; Kastrati A; von Beckerath N
Thromb Haemost; 2009 Apr; 101(4):714-9. PubMed ID: 19350116
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
[TBL] [Abstract][Full Text] [Related]
7. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.
Siller-Matula JM; Spiel AO; Lang IM; Kreiner G; Christ G; Jilma B
Am Heart J; 2009 Jan; 157(1):148.e1-5. PubMed ID: 19081411
[TBL] [Abstract][Full Text] [Related]
8. The clopidogrel conundrum.
Bertino JS
J Clin Pharmacol; 2014 Aug; 54(8):841-2. PubMed ID: 25044099
[No Abstract] [Full Text] [Related]
9. The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.
Liu Q; Dang DS; Chen YF; Yan M; Shi GB; Zhao QC
Genet Test Mol Biomarkers; 2012 Nov; 16(11):1293-7. PubMed ID: 23046071
[TBL] [Abstract][Full Text] [Related]
10. Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Neubauer H; Engelhardt A; Krüger JC; Lask S; Börgel J; Mügge A; Endres HG
J Cardiovasc Pharmacol; 2010 Jul; 56(1):91-7. PubMed ID: 20410834
[TBL] [Abstract][Full Text] [Related]
11. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
12. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
Furuta T; Iwaki T; Umemura K
Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
[TBL] [Abstract][Full Text] [Related]
14. Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit?
Serebruany V; Goto S
Thromb Haemost; 2009 Apr; 101(4):607-9. PubMed ID: 19350100
[No Abstract] [Full Text] [Related]
15. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
16. [Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes].
Lu FM; Tong ZL; Mao YM; Wu DY; Xu J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Aug; 29(4):478-81. PubMed ID: 22875511
[TBL] [Abstract][Full Text] [Related]
17. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
Cuisset T; Frere C; Quilici J; Poyet R; Gaborit B; Bali L; Brissy O; Morange PE; Alessi MC; Bonnet JL
J Am Coll Cardiol; 2009 Sep; 54(13):1149-53. PubMed ID: 19761935
[TBL] [Abstract][Full Text] [Related]
18. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
19. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.
Fontes-Carvalho R; Albuquerque A; Araújo C; Pimentel-Nunes P; Ribeiro VG
Eur J Gastroenterol Hepatol; 2011 May; 23(5):396-404. PubMed ID: 21464720
[TBL] [Abstract][Full Text] [Related]
20. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.
Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Kagami T; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K; Umemura K
J Thromb Thrombolysis; 2017 Apr; 43(3):333-342. PubMed ID: 27981489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
